{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:09:49Z","timestamp":1793736589028,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011338","name":"AstraZeneca AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacc.2025.05.033","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:06:41Z","timestamp":1753711601000},"page":"320-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Vasques-N\u00f3voa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e9nio","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Filipa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1tia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia O.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Santos-Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-8552","authenticated-orcid":false,"given":"Fernando","family":"Fri\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e2ndida","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Tiago","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria In\u00eas","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-6825","authenticated-orcid":false,"given":"Gualter","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Pereira-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Pimenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-8393","authenticated-orcid":false,"given":"Ricardo","family":"Fontes-Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.05.033_bib1","article-title":"Rising incidence of heart failure demands action","author":"Zannad","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.05.033_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.05.033_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.05.033_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.05.033_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.05.033_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.05.033_bib7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.05.033_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.05.033_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1585","article-title":"Heart failure around the world","author":"Tromp","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib10","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1093\/eurheartj\/ehad522","article-title":"Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis","volume":"44","author":"Banerjee","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacc.2025.05.033_bib11","first-page":"236","article-title":"Mineralocorticoid receptor antagonist combined with SGLT2 inhibitor versus SGLT2 inhibitor alone in chronic kidney disease: a meta-analysis of randomized trials","volume":"56","author":"Ferreira","year":"2025","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jacc.2025.05.033_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib13","article-title":"Sodium-glucose cotransporter-2 inhibitor with and without aldosterone antagonist for heart failure with preserved ejection fraction: design paper","author":"Ferreira","year":"2025","journal-title":"ESC: Heart Failure"},{"key":"10.1016\/j.jacc.2025.05.033_bib14","author":"Pellicori","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.010661","article-title":"Evolution of NT-proBNP during prerandomization screening in VICTORIA: implications for clinical outcomes and efficacy of vericiguat","volume":"16","author":"Armstrong","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib16","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic implications of changes in N-terminal pro\u2013B-type natriuretic peptide in patients with heart failure","volume":"68","author":"Zile","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.05.033_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004743","article-title":"Role of B-type natriuretic peptide and N-terminal prohormone BNP as predictors of cardiovascular morbidity and mortality in patients with a recent coronary event and type 2 diabetes mellitus","volume":"6","author":"Wolsk","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.05.033_bib18","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.0000144310.04433.BE","article-title":"N-terminal\u2013pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients","volume":"10","author":"Bettencourt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.05.033_bib19","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.jacc.2016.09.936","article-title":"Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials","volume":"68","author":"Ferreira","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.05.033_bib20","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.05.033_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.05.033_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jchf.2022.05.004","article-title":"Prognostic implications of N-terminal pro\u2013B-type natriuretic peptide and high-sensitivity cardiac troponin T in EMPEROR-Preserved","volume":"10","author":"Januzzi","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006638","article-title":"Mechanistic effects of spironolactone on cardiovascular and renal biomarkers in heart failure with preserved ejection fraction: a TOPCAT biorepository study","volume":"13","author":"Myhre","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib24","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1002\/ehf2.14542","article-title":"Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients","volume":"10","author":"Nasab Mehrabi","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ejhf.3136","article-title":"Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Preserved","volume":"26","author":"Rastogi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"9","author":"McCausland","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.05.033_bib27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2024.11.020","article-title":"Initial decline in glomerular filtration rate with finerenone in HFmrEF\/HFpEF: a prespecified analysis of FINEARTS-HF","volume":"85","author":"Matsumoto","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.05.033_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial","volume":"20","author":"Neefs","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2025.05.033_bib30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ejhf.2861","article-title":"Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation","volume":"25","author":"Filippatos","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.05.033_bib32","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/ejhf.2982","article-title":"Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE","volume":"25","author":"Ferreira","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jacc.2011.09.062","article-title":"Effects of vasodilation in heart failure with preserved or reduced ejection fraction: implications of distinct pathophysiologies on response to therapy","volume":"59","author":"Schwartzenberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.05.033_bib34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/eurjhf\/hfr070","article-title":"Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes","volume":"13","author":"Testani","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/clpt.1985.206","article-title":"New insights into the pharmacokinetics of spironolactone","volume":"38","author":"Overdiek","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2025.05.033_bib37","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT \u2014 new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.05.033_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1909","article-title":"Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ejhf.2409","article-title":"Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib41","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.05.033_bib42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.05.033_bib43","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.05.033_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/CIRCULATIONAHA.124.072055","article-title":"Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure","volume":"151","author":"Vaduganathan","year":"2025","journal-title":"Circulation"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725065994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725065994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:27:56Z","timestamp":1787646476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725065994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0735109725065994"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.05.033","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter 2 Inhibitor With and Without an Aldosterone Antagonist for Heart Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}